Swipe om te navigeren naar een ander artikel
Evidence from previous studies has suggested there may be physical and mental changes in health among testicular cancer survivors. No studies have been conducted in the United States, however.
Study participants were initially enrolled in the US Servicemen’s Testicular Tumor Environmental and Endocrine Determinants (STEED) study between 2002 and 2005. A total of 246 TGCT (testicular germ cell tumor) cases and 236 non-testicular cancer controls participated in the current study, and completed a self-administered questionnaire. Mean time since diagnosis for cases was 14 years, and no less than five for all cases. Component scores determined from responses to questions about physical and mental health on SF36 were tabulated to yield two summary measures, physical component scores (PCS), and mental component scores (MCS). Component and summary scores were normalized to a score of 50 with a standard deviation of 10 by a linear T-score transformation.
Overall, cases may not suffer greatly in different quality of life than controls. When all cases and controls are compared, TGCT cases had lower PCS (mean: 51.9 95% CI: 50.6–53.2, P value: 0.037) than controls (mean: 53.6 95% CI: 52.7–54.6). MCS were not significantly different (P value: 0.091). In multivariate analyses, several physical health components were worse for TGCT cases such as role-physical (OR 1.19, 95% CI: 1.01–1.39) and general health (OR 1.26, 95% CI: 1.07–1.49) compared to controls. However, TGCT cases treated with chemotherapy had lower PCS (cases: 50.2, 95% CI: 47.6–52.8; controls: 53.6, 95% CI: 52.7–54.6, P value: 0.0032) and MCS (cases: 49.3, 95% CI: 46.5–52.1; controls: 52.0, 95% CI: 50.9–53.2, P value: 0.039). TGCT cases who received treatments other than chemotherapy did not differ from controls in either PCS or MCS.
Physical and general health limitations may affect testicular cancer survivors. Men treated with chemotherapy, however, may be most likely to suffer adverse health outcomes due to a combination of body-wide effects on physical and mental factors which affect various aspects of physical health, mental health, and overall quality of life. And in particular, physical functioning, role–physical, and general health are strongly affected.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Cancer Reference Information. (2009). American Cancer Society.
McGlynn, K. A., Devesa, S. S., Sigurdson, A. J., Brown, L. M., Tsao, L., & Tarone, R. E. (2003). Trends in the incidence of testicular germ cell tumors in the United States. Cancer,91, 63–70. CrossRef
Grosfeld, G., & Small, E. (1998). Long-term side effects of treatment for testis cancer. Urologic Clinics of North America,25(3), 503–515. CrossRef
Arai, Y., Ishitoya, S., Okubo, K., Aoki, Y., Okada, T., Maeda, H., et al. (1997). Nerve-sparing retroperitoneal lymph node dissection for metastatic testicular cancer. Int J Urology,4(5), 487–492. CrossRef
Bokemeyer, C., Berger, C. C., Kuczyk, M. A., & Schmoll, H. J. (1996). Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Onc,14, 2923–2932.
Fossa, S. D., de Wit, R., Roberts, J. T., Wilkinson, P. M., de Mulder, P. H. M., Mead, G. M., et al. (2003). Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the european organization for research and treatment of cancer genitourinary group/medical research council testicular cancer study group (30941/TE20). J Clin Onc,21(6), 1107–1118. CrossRef
Huddart, R. A., Norman, A., Shahidi, M., Horwich, A., Coward, D., Nicholls, J., et al. (2003). Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Onc,21(8), 1513–1523. CrossRef
Meinardi, M. T., Gietema, J. A., van der Graaf, W. T. A., van Veldhuisen, D. J., Runne, M. A., Sluiter, W. J., et al. (2000). Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Onc,18(8), 1725–1732.
van den Belt-Dusebout, A. W., de Wit, R., Gietema, J. A., Horenblas, S., Louwman, M. W. J., Ribot, J. G., et al. (2007). Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Onc,25(28), 4370–4378. CrossRef
van den Belt-Dusebout, A. W., Nuver, J., de Wit, R., Gietema, J. A., ten Bokkel Huinink, W. W., Rodrigus, P. T. R., et al. (2006). Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Onc,24(3), 467–475. CrossRef
Vogelzang, N. J., Bosl, G. J., Johnson, K., & Kennedy, B. J. (1981). Raynaud’s phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Annals of Internal Medicine,95(3), 288–292. PubMed
Kollmannsberger, C., Kuzcyk, M., Mayer, F., Hartmann, J. T., Kanz, L., & Bokemeyer, C. (1999). Late toxicity following curative treatment of testicular cancer. Seminars,17(4), 275–281.
McHrney, C. A., Ware, J. E., Lu, J. F., & Sherbourne, C. D. (1994). The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Medical Care,32(1), 40–66. CrossRef
Kosinski, M., Keller, S. D., Hatoum, H. T., Kong, S. X., & Ware, J. E. (1999). The SF-36 Health Survey as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis: tests of data quality, scaling assumptions and score reliability. Medical Care,37(5), MS10–MS22. PubMedCrossRef
Joly, F., Heron, J. F., Kalusinski, L., Bottet, P., Brunce, D., Allouache, N., et al. (2002). Quality of life in long-term survivors of testicular cancer: a population-based case-control study. J Cln Onc,20(1), 73–80. CrossRef
Mykletun, A., Dahl, A. A., Haaland, C. F., Bremnes, R., Dahl, O., Klepp, O., et al. (2005). Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. J Clin Onc,23(13), 3061–3068. CrossRef
Rudberg, L., Nilsson, S., & Wikblad, K. (2000). Health-related quality of life in survivors of testicular cancer 3 to 13 years after treatment. J Psychosocial Oncology,18(3), 19–31. CrossRef
Ware, J., Kosinski, M., & Dewey, J. (2000). How to score version 2 of the SF-36 health survey (standard & acute forms). In. Lincoln, RI: QualityMetric Incorporated.
Kosinski, M., Keller, S. D., Ware, J. E., Hatoum, H. T., & Kong, S. X. D. (1999). The SF-36 Health Survey as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis—Relative validity of scales in relation to clinical measures of arthritis severity. Medical Care,37(5), MS23–MS39. PubMedCrossRef
Khanna, D., Furst, D. E., Clements, P. J., Park, G. S., Hays, R. D., Yoon, J., et al. (2005). Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. Journal of Rheumatology,32(5), 832–840. PubMed
Chambers, B. A., Guo, S. S., Siervogel, R., Hall, G., & Chumlea, W. C. (2002). Cumulative effects of cardiovascular disease risk factors on quality of life. J Nutr Health Aging,6(3), 179–184. PubMed
Fossa, S. D., Dahl, A. A., & Loge, J. H. (2003). Fatigue, anxiety, and depression in long-term survivors of testicular cancer. J Clin Onc,21(7), 1249–1254. CrossRef
Dahl, A. A., Haaland, C. F., Mykletun, A., Bremnes, R., Dahl, O., Klepp, O., et al. (2005). Study of anxiety disorder and depression in long-term survivors of testicular cancer. J Clin Onc,23(10), 2389–2395. CrossRef
Arai, Y., Mawakita, M., Hida, S., Terachi, T., Okada, Y., & Yoshida, O. (1996). Psychosocial aspects in long-term survivors of testicular cancer. Clinical Urology,155(2), 574–578.
Kubo, C. (2003). Stress and immune function. J Japan Med Assoc,46(2), 50–54.
Jenkinson, C., Peto, V., Fitzpatrick, R., Greenhall, R., & Hyman, N. (1995). Self-reported functioning and well-being in patients with Parkinson’s disease: comparison of the short-form health survey (SF-36) and the Parkinson’s Disease Questionnaire (PDQ-39). Age and Ageing,24(6), 505–509. PubMedCrossRef
- Quality of life among testicular cancer survivors: a case–control study in the United States
Katherine A. McGlynn
Ralph L. Erickson
David W. Niebuhr
Kathryn Hughes Barry
- Springer Netherlands